Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Shares Down 1.1% – Here’s Why

Shares of Valion Bio, Inc. Common Stock (NASDAQ:VBIO) traded down 1.1% during mid-day trading on Monday . The stock traded as low as $0.47 and last traded at $0.5139. 180,809 shares traded hands during mid-day trading, a decline of 59% from the average session volume of 437,637 shares. The stock had previously closed at $0.5195.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a research note on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Valion Bio, Inc. Common Stock Price Performance

The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.02 and a current ratio of 3.31. The company has a 50-day moving average of $0.89 and a 200-day moving average of $1.11. The firm has a market capitalization of $1.64 million, a price-to-earnings ratio of -0.08 and a beta of 1.79.

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) last announced its earnings results on Thursday, May 14th. The company reported ($2.23) EPS for the quarter.

About Valion Bio, Inc. Common Stock

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.